If you are at higher risk of breast cancer, screening looks set to change. Here’s what we know so far.
Articles on Breast density
Displaying all articles
More women are learning about their breast density when they receive their mammogram results. But what happens next?
As breast cancer screening evolves, understanding personal risk factors like density is critical for improving early detection.
Cancers and dense tissue both show up white on a mammogram.
The FDA’s rule change requires that all women in the US be informed about breast density and options for supplemental screening.
Corporate medicine is hijacking feminist narratives around empowerment and women’s rights to market technologies, tests and treatments that aren’t backed by evidence.
Dense breast tissue is common and normal, but it can make cancer more difficult to detect. FDA requirements going into effect in September 2024 will dictate that patients be better informed about it.
Top contributors
-
NHMRC Emerging Leader Research Fellow, School of Public Health, University of Sydney
-
Principal Research Fellow, School of Population and Global Health, The University of Western Australia
-
NHMRC Emerging Leader Research Fellow in Reproductive Health, School of Public Health, University of Sydney
-
Emeritus Professor of Medicine, Boston University
-
Professor of Public Health, University of Sydney
-
Associate Director of Cancer Care Equity, Yale Cancer Center, Yale University
-
Assistant Professor of Health Policy and Clinical Practice, Dartmouth College
-
Professor of Biomedical Sciences, Anglia Ruskin University
-
Professor of Radiology, Boston University
-
Professor of Radiology, School of Medicine, University of Pittsburgh